Does the media prefer LUCD or ACRS?

In the previous week, Aclaris Therapeutics had 5 more articles in the media than Lucid Diagnostics. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 9 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.14 beat Aclaris Therapeutics' score of 0.07 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LUCD or MNPR?

In the previous week, Monopar Therapeutics had 5 more articles in the media than Lucid Diagnostics. MarketBeat recorded 14 mentions for Monopar Therapeutics and 9 mentions for Lucid Diagnostics. Monopar Therapeutics' average media sentiment score of 1.00 beat Lucid Diagnostics' score of 0.14 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LUCD or CADL?

In the previous week, Candel Therapeutics had 10 more articles in the media than Lucid Diagnostics. MarketBeat recorded 19 mentions for Candel Therapeutics and 9 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.14 beat Candel Therapeutics' score of -0.02 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Candel Therapeutics 2 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer AURA or LUCD?

In the previous week, Aura Biosciences had 19 more articles in the media than Lucid Diagnostics. MarketBeat recorded 28 mentions for Aura Biosciences and 9 mentions for Lucid Diagnostics. Aura Biosciences' average media sentiment score of 0.47 beat Lucid Diagnostics' score of 0.14 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 3 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LUCD or IRWD?

In the previous week, Lucid Diagnostics had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for Lucid Diagnostics and 8 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.85 beat Lucid Diagnostics' score of 0.14 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Lucid Diagnostics (LUCD) Competitors

$0.97 +0.00 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 +0.02 (+1.68%)

As of 07:44 PM Eastern

Compare

LUCD vs. ACRS, MNPR, CADL, AURA, and IRWD

Should you buy Lucid Diagnostics stock or one of its competitors? Lucid Diagnostics's main competitors and comparable companies include Aclaris Therapeutics (ACRS), Monopar Therapeutics (MNPR), Candel Therapeutics (CADL), Aura Biosciences (AURA), and Ironwood Pharmaceuticals (IRWD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lucid Diagnostics compare to Aclaris Therapeutics?

Lucid Diagnostics (NASDAQ:LUCD) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Lucid Diagnostics has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	41.76	-$58.01M	-$0.47	N/A
Aclaris Therapeutics	$7.83M	103.21	-$64.92M	-$0.58	N/A

Aclaris Therapeutics has a net margin of -921.50% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

In the previous week, Aclaris Therapeutics had 5 more articles in the media than Lucid Diagnostics. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 9 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.14 beat Aclaris Therapeutics' score of 0.07 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lucid Diagnostics currently has a consensus price target of $4.19, suggesting a potential upside of 332.73%. Aclaris Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 98.96%. Given Lucid Diagnostics' higher probable upside, research analysts plainly believe Lucid Diagnostics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lucid Diagnostics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Summary

Lucid Diagnostics and Aclaris Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to Monopar Therapeutics?

Lucid Diagnostics (NASDAQ:LUCD) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Lucid Diagnostics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

Monopar Therapeutics has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Monopar Therapeutics	N/A	-13.08%	-12.79%

In the previous week, Monopar Therapeutics had 5 more articles in the media than Lucid Diagnostics. MarketBeat recorded 14 mentions for Monopar Therapeutics and 9 mentions for Lucid Diagnostics. Monopar Therapeutics' average media sentiment score of 1.00 beat Lucid Diagnostics' score of 0.14 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Lucid Diagnostics currently has a consensus price target of $4.19, suggesting a potential upside of 332.73%. Monopar Therapeutics has a consensus price target of $117.42, suggesting a potential upside of 3.87%. Given Lucid Diagnostics' higher probable upside, equities analysts plainly believe Lucid Diagnostics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Monopar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Monopar Therapeutics has lower revenue, but higher earnings than Lucid Diagnostics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	41.76	-$58.01M	-$0.47	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Summary

Monopar Therapeutics beats Lucid Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to Candel Therapeutics?

Lucid Diagnostics (NASDAQ:LUCD) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Candel Therapeutics has lower revenue, but higher earnings than Lucid Diagnostics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	41.76	-$58.01M	-$0.47	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Lucid Diagnostics presently has a consensus target price of $4.19, suggesting a potential upside of 332.73%. Candel Therapeutics has a consensus target price of $19.29, suggesting a potential upside of 64.55%. Given Lucid Diagnostics' higher probable upside, equities analysts plainly believe Lucid Diagnostics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Candel Therapeutics had 10 more articles in the media than Lucid Diagnostics. MarketBeat recorded 19 mentions for Candel Therapeutics and 9 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.14 beat Candel Therapeutics' score of -0.02 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	2 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Candel Therapeutics has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Candel Therapeutics	N/A	-84.70%	-54.37%

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lucid Diagnostics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, suggesting that its share price is 151% less volatile than the broader market.

Summary

Lucid Diagnostics beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Lucid Diagnostics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Aura Biosciences had 19 more articles in the media than Lucid Diagnostics. MarketBeat recorded 28 mentions for Aura Biosciences and 9 mentions for Lucid Diagnostics. Aura Biosciences' average media sentiment score of 0.47 beat Lucid Diagnostics' score of 0.14 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	3 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aura Biosciences has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Lucid Diagnostics	-959.76%	N/A	-119.57%

Aura Biosciences presently has a consensus price target of $17.50, indicating a potential upside of 127.57%. Lucid Diagnostics has a consensus price target of $4.19, indicating a potential upside of 332.73%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Lucid Diagnostics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Lucid Diagnostics	$4.71M	41.76	-$58.01M	-$0.47	N/A

Aura Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Lucid Diagnostics beats Aura Biosciences on 10 of the 15 factors compared between the two stocks.

How does Lucid Diagnostics compare to Ironwood Pharmaceuticals?

Lucid Diagnostics (NASDAQ:LUCD) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Ironwood Pharmaceuticals has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	41.76	-$58.01M	-$0.47	N/A
Ironwood Pharmaceuticals	$296.15M	2.40	$24.02M	$0.77	5.60

74.0% of Lucid Diagnostics shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lucid Diagnostics presently has a consensus target price of $4.19, indicating a potential upside of 332.73%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 44.62%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Lucid Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

In the previous week, Lucid Diagnostics had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for Lucid Diagnostics and 8 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.85 beat Lucid Diagnostics' score of 0.14 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

Summary

Ironwood Pharmaceuticals beats Lucid Diagnostics on 9 of the 17 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUCD vs. The Competition

Export

Metric	Lucid Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$196.11M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-2.06	10.67	269.06	25.28
Price / Sales	41.76	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	19.35	16.78	12.91	6.24
Net Income	-$58.01M	-$13.32M	$3.45B	$347.60M
7 Day Performance	0.06%	1.74%	1.12%	1.07%
1 Month Performance	-3.23%	1.60%	1.79%	1.03%
1 Year Performance	-1.37%	56.43%	67.69%	20.77%

Lucid Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUCD Lucid Diagnostics	3.3122 of 5 stars	$0.97 +0.3%	$4.19 +332.7%	-1.7%	$196.11M	$4.71M	N/A	70	News Coverage Earnings Report
ACRS Aclaris Therapeutics	2.0704 of 5 stars	$5.98 +8.1%	$11.50 +92.3%	+244.7%	$772.34M	$7.83M	N/A	100	Analyst Revision
MNPR Monopar Therapeutics	1.9624 of 5 stars	$118.46 +6.1%	$112.08 -5.4%	+229.5%	$747.88M	N/A	N/A	10	Earnings Report Analyst Forecast Analyst Revision
CADL Candel Therapeutics	1.9654 of 5 stars	$10.51 +4.4%	$18.57 +76.7%	+84.4%	$737.83M	N/A	N/A	60	Trending News Earnings Report Analyst Forecast Analyst Revision
AURA Aura Biosciences	2.0159 of 5 stars	$7.15 +1.6%	$20.50 +186.7%	+5.8%	$727.84M	N/A	N/A	50	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUCD) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lucid Diagnostics (LUCD) Competitors

LUCD vs. ACRS, MNPR, CADL, AURA, and IRWD

How does Lucid Diagnostics compare to Aclaris Therapeutics?

Summary

How does Lucid Diagnostics compare to Monopar Therapeutics?

Summary

How does Lucid Diagnostics compare to Candel Therapeutics?

Summary

How does Lucid Diagnostics compare to Aura Biosciences?

Summary

How does Lucid Diagnostics compare to Ironwood Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lucid Diagnostics (LUCD) Competitors

LUCD vs. ACRS, MNPR, CADL, AURA, and IRWD

How does Lucid Diagnostics compare to Aclaris Therapeutics?

Which has preferable valuation & earnings, LUCD or ACRS?

Is LUCD or ACRS more profitable?

Does the media prefer LUCD or ACRS?

Do analysts rate LUCD or ACRS?

Do institutionals & insiders hold more shares of LUCD or ACRS?

Which has more risk and volatility, LUCD or ACRS?

Summary

How does Lucid Diagnostics compare to Monopar Therapeutics?

Which has more volatility & risk, LUCD or MNPR?

Is LUCD or MNPR more profitable?

Does the media favor LUCD or MNPR?

Do analysts recommend LUCD or MNPR?

Do insiders and institutionals hold more shares of LUCD or MNPR?

Which has better valuation and earnings, LUCD or MNPR?

Summary

How does Lucid Diagnostics compare to Candel Therapeutics?

Which has preferable earnings & valuation, LUCD or CADL?

Do analysts recommend LUCD or CADL?

Does the media favor LUCD or CADL?

Is LUCD or CADL more profitable?

Do institutionals & insiders hold more shares of LUCD or CADL?

Which has more risk and volatility, LUCD or CADL?

Summary

How does Lucid Diagnostics compare to Aura Biosciences?

Does the media prefer AURA or LUCD?

Is AURA or LUCD more profitable?

Do analysts recommend AURA or LUCD?

Which has higher valuation & earnings, AURA or LUCD?

Which has more risk & volatility, AURA or LUCD?

Do institutionals and insiders have more ownership in AURA or LUCD?

Summary

How does Lucid Diagnostics compare to Ironwood Pharmaceuticals?

Which has better earnings and valuation, LUCD or IRWD?

Do institutionals and insiders believe in LUCD or IRWD?

Do analysts prefer LUCD or IRWD?

Which has more volatility and risk, LUCD or IRWD?

Does the media prefer LUCD or IRWD?

Is LUCD or IRWD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools